Signal Capital Names Biotech. Expert Vice Chairman

Jul 31 2009 | 9:46am ET

Alternative investments firm Signal Capital Management has named a biotech expert as executive and academic vice chairman.

Roger van Hanwehr is CEO of energy technology development company Solus and co-founder of consulting firm Arcxeon. He also teaches biotechnology at Georgetown University in Washington, D.C.

Hanwehr, a polymath with expertise in such diverse fields as biological and radiological defense, renewable energy and nanotechnology, will evaluate investment opportunities in his new role at Signal.


In Depth

GSAM's Papagiannis: Liquid Alternatives For The Long Run

Apr 21 2017 | 8:44pm ET

Interest in liquid alternatives cooled a bit last year amid a broad shift in investor...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Debunking Conventional Investment Wisdom (Part II)

Apr 17 2017 | 5:56pm ET

The alternative investment industry is currently replete with buzzwords around data...

 

From the current issue of